Abstract Aging is a major driver of cardiovascular (CV) disease. Incidence of stroke and myocardial infarction increases, and is associated with worsening outcomes, in relation to patient age. Therefore, by studying chronological age in relation to other CV risk factors, pertinent mechanisms of senescence and disease in the heart and blood vessels can be delineated. This is a rather complex process that entails activation of detrimental molecular pathways. An emerging science is revealing intricate signalling cascades which may explain why cardiac and vascular aging are accelerated in the context of CV risk factors. The identification of novel molecular pathways may provide critical insights for mechanism-based therapeutic strategies to prevent premature aging and related CV disease burden. Our lab, as well as other investigators, has recently identified aging and longevity genes and their participation to early vascular and cardiac disease. In the present review, we discuss recent advances in the pathophysiology of agerelated vascular and myocardial disease: i) altered nitric oxide signalling as a determinant of vascular and microvascular dysfunction; ii) determinants of mitochondrial oxidative stress; iii) emerging links between oxidant and inflammatory genes; and iv) mechanisms of endothelial and cardiac progenitor cell dysfunction as well as therapeutic implications for vascular and myocardial repair. Such a mechanistic overview illuminates attractive molecular targets for the prevention of age-driven pathology in the vasculature and the heart.
Introduction
Age is one of the major risk factors associated with cardiovascular disease [1] . Aging of the heart and vessels is a rather complex process ensuing in the deterioration of tissue structure and functionality [2] . Time-dependent changes occurring in the CV system are certainly aggravated by concomitant risk factors such as hypertension, smoking and diabetes [3] . Indeed, clustering of these conditions anticipates physiological aging, resulting in early features of cardiac and vascular senescence [4] . The synergic effect of aging and other risk factors is an important driver of myocardial infarction, stroke and CV death. Indeed, available heart age calculators include common modifiable and non-modifiable risk factors [5] . These tools are being widely used among the general population and may help to monitor and eventually improve individual CV health status. In the absence of other risk factors or CV disease, the heart age of a 30-year-old man who smokes is six years higher than expected. Such an example confirms that risk factors precipitate CV aging. Therefore, the term "aging" may be misinterpreted since it refers only to the "passage of time". Conversely, aging of the heart and vessels is driven by challenging factors and should be considered as a picture of global CV risk. Although experimental studies have shown that aging per se triggers endothelial dysfunction and atherosclerosis [6] , it remains difficult to understand its real impact since CV risk factors advance as time goes by.
Pathological Features of Cardiovascular Aging
Clinical and pre-clinical data have shown that aging is associated with structural and functional properties of large arteries [7, 8] . In aged healthy humans these alterations are represented by luminal dilation, increased arterial stiffness, endothelial dysfunction and diffuse intimal thickening. Elastic proximal arteries such as the central aorta and the carotid artery dilate with age, resulting in increased lumen diameter. Aging also leads to a progressive thickening of the media with subsequent vascular stiffness. Increased stiffness may be the result of different factors including enhanced elastin degradation and collagen deposition in the vascular media [9, 10] . Importantly, remodelling of the vasculature is accompanied by key alterations of endothelial homeostasis. Occurrence of endothelial dysfunction is a major cause of morbidity and mortality [11] . Seminal studies have clearly shown that endothelium-dependent vasorelaxation is impaired in aged vessels and this phenomenon is associated with increased vascular permeability and inflammation as well as impaired angiogenesis (see Fig. 1 ) [6, [12] [13] [14] . The endothelial layer is an active tissue orchestrating a fine balance between vasodilating and vasoactive factors [15] . Age-related alterations of endothelial cell functionality may, in turn, aggravate media thickness and vascular fibrosis. Beside abnormalities of the vascular bed, the aging process certainly affects heart structure and function [16] . Heart weight increases with age, regardless of blood pressure values. By contrast, the number of cardiac myocytes progressively decreases, suggesting that hypertrophy and fibrosis are major hallmarks of the aged heart. This continued loss of functional cardiac cells is paralleled by a decline in regenerative activity from 1 % per year at age 20 to 0.4 % at 75 years [17] . Fibrosis in the aged myocardium serves as a pathological substrate for potential arrhythmias, namely atrial fibrillation. An important pathological feature associated with aging is the calcification of aortic and mitral valves which triggers stenosis/insufficiency resulting in cardiac pressure/volume overload. Moreover, the number of cells in the sino-atrial node decreases and this explains chronotropic incompetence in response to maximum exercise. Such age-dependent decline of cardiac functional reserve may predispose elderly people to heart failure [18] . Myocardial fibrosis and stiffness concur to the impairment of left ventricular compliance, leading to a pre-clinical decline of diastolic and systolic function [19] .
Nitric Oxide as a Determinant of Vascular and Microvascular Function
Nitric oxide (NO) is the most important vasodilator produced by endothelial NO synthase (eNOS) and is a marker of vascular health [20] . Indeed, reduced NO bioavailability is a strong predictor of CV events [21] . Impaired NO bioavailability is observed in hypertension, diabetes and atherosclerosis [22, 23] . Notably, experimental and human studies have shown that aging leads to reduced NO production and endothelial dysfunction, regardless of other risk factors [24, 25••, 26, 27] . Aging may impair eNOS functionality via several mechanisms [10] . A deficiency in eNOS substrates and cofactors plays a pivotal role.
L-arginine, a major eNOS substrate, is rapidly degraded by arginase II, leading to decreased substrate availability and reduced NO synthesis [28] . Interestingly, arginase II activity and expression increase with age, thus contributing to endothelial dysfunction in this setting [29] . Arginase II may represent an attractive target for the prevention of age-related endothelial dysfunction since a recent study showed that arginase inhibition improves brachial artery vasodilation in diabetic subjects [30] . Pharmacological suppression of arginase activity may indeed restore physiological substrate levels and improve vascular functionality in elderly individuals (see Fig. 1 ). Very recently, arginase II upregulation has shown to mediate age-related decrease of the cardiac contractile reserve [31] . This latter observation suggests a potential role of arginase inhibition also for the prevention of heart failure.
Beside L-arginine, tetrahydrobiopterin (BH4) is an important cofactor for eNOS activity involved in age-related endothelial dysfunction (see Fig. 1 ) [28] . Indeed, increased oxidative stress rapidly degrades BH4 resulting in altered eNOS efficiency whereas exogenous administration improves endothelium-dependent vasodilation in human aging [32] . Moreover, Akt-dependent eNOS active phosphorylation at Ser1177 is significantly reduced in aged vessels and accounts for impaired vasorelaxation in large arteries as well as in the collateral circulation [1] .
Alteration of eNOS transcription may be also involved in endothelial dysfunction but its biological significance remains unclear. Many studies found increased eNOS expression in aging [14] and such an observation has been interpreted as a compensatory but futile mechanism to counterregulate the loss of NO [14] . Preservation of NO signalling is required for the maintenance of coronary microvascular function, an important determinant of myocardial viability and energetics [33] . Age-dependent alterations at the level of the coronary circulation may play an important role in the evolution of left ventricular fibrosis and function. Indeed, age-related eNOS dysfunction is critically involved in microvascular dysfunction and impaired ventricular contractility in elderly patients [34] .
Advanced age is also associated with decreased angiographic presence of collaterals to the infarct-related artery in patients with acute myocardial infarction. This abnormality may contribute to the poor prognosis of elderly patients with acute coronary syndromes [35] . Collectively, this evidence strongly suggests that modulation of eNOS functionality is a promising target for the prevention of age-related vascular disease (see Fig. 1 ).
Mitochondrial Reactive Oxygen Species
A major feature of CV aging is the imbalance between NO bioavailability and accumulation of reactive oxygen species (ROS) [14] , leading to endothelial dysfunction [36, 37] . Indeed, age-dependent generation of the superoxide anion (O 2 -) inactivates NO to form peroxynitrite (ONOO -), a powerful oxidant which easily penetrates across phospholipid membranes and induces substrate nitration [14] . Protein nitrosylation blunts activity of antioxidant enzymes and endothelial NO synthase [38] . Generation of ROS into the vessel wall has been postulated as a major pathophysiological step favouring aging of arteries [1] . Among the different aging theories, the mitochondrial free radical theory of aging has taken center stage for several decades. According to this assumption, ROS are considered to be a detrimental toxic bioproduct of aerobic metabolism that induce oxidative cellular damage due to their high chemical reactivity. ROS are small molecules highly reactive because of the presence of unpaired electrons. They are generated within the cell as byproducts of several metabolic and enzymatic pathways. However, the majority of cellular ROS are generated within the mitochondrial oxidative phosphorylation. During this process, electrons are extracted from NADH and FADH and transferred to molecular oxygen through a chain of four enzymatic complexes ensuring phosphorylation of ADP in ATP and final reduction of molecular oxygen to water [6] . Indeed, electrons derived from NADH or FADH can directly react with oxygen or other electron acceptors within the mitochondrial electron transport chain and generate free radicals. Accumulation of ROS causes mitochondrial disruption leading to cytochrome c release and subsequent activation of caspase 3 [37] . CV risk factors such as hyperglycemia induce a ROS-dependent alteration of the mitochondrial network resembling early signs of vascular aging [39] . Indeed, endothelial cells isolated from middle-age diabetic subjects show a premature derangement of organelle structure which correlated with impaired flow mediated vasodilation of the brachial artery [39] .
Vascular and Cardiac Effects of Aging and Longevity Genes
Mitochondrial Adaptor p66 Shc Given the importance of oxidative signals in the biology of vascular aging, it is important to elucidate the molecular machineries involved in such a phenomenon. In recent years Shc−/− mouse models exposed to high oxidative stress. [6] . The p66
Shc adaptor protein functions as a redox enzyme implicated in mitochondrial ROS generation and translation of oxidative signals into apoptosis (see Fig. 1 ) [6, 24, [40] [41] [42] .
Several chronic stimuli activate the protein kinase C βII (PKCβII) isoform to induce Ser-36 phosphorylation of p66 Shc , allowing transfer of the protein from the cytosol to the mitochondrion where it catalyzes ROS production via cytochrome c oxidation [42] . This latter event leads to mitochondrial disruption and cell death. Indeed, increased ROS generation alters mitochondrial permeability facilitating the release of intermembrane space proapoptotic proteins such as cytochrome c [42] . Once released in the cytosol, cytochrome c is responsible for activation of the apoptosis execution enzyme caspase. Accordingly, mice lacking the p66
Shc gene (p66
) display a prolonged lifespan, increased resistance to oxidative stress, and apoptosis.
We have previously reported that endothelium-dependent relaxation in response to acetylcholine was age-dependently impaired in WT mice but not in p66
Shc−/− mice [24] . Accordingly, p66
Shc−/− mice were protected against the age-related decline of NO release. This study suggests that p66
Shc signalling is required to induce a ROS-driven vascular senescent phenotype. [24] . Importantly, p66
Shc activation is thought to be upstream of NADPH as well as a mammalian target of the rapamycin (mTOR) pathway, two important determinants of vascular damage [43] [44] [45] .
Activation of p66 Shc also interferes with the progression into the senescent heart phenotype and the development of heart failure in diabetic mice [46] . Indeed, diabetic p66
Shc−/− mice were protected against myocardial oxidative stress, apoptosis and telomere shortening [46] . Moreover, ablation of the p66
Shc gene in cardiac stem cells preserved the growth reserve of the heart [46] . Although these studies provide interesting insights into the role of p66
Shc in CV aging, it remains unclear whether protein inhibition may reverse vascular disease phenotype. In this regard, we have demonstrated for the first time that in vivo RNA interference blunts vascular p66
Shc expression, ROS generation and endothelial dysfunction in diabetic mice [47] . Our findings suggest that p66
Shc inhibition may prevent or delay the development of age-related CV disease such as myocardial infarction and stroke.
The clinical relevance of p66 Shc is supported by the notion that p66
Shc gene expression is increased in mononuclear cells obtained from patients with type 2 diabetes and coronary artery disease [48, 49] . A recent study showed that p66 Shc expression is higher in fibroblasts isolated from centenarians [50] . This finding likely indicates that p66
Shc expression may increase in a time-dependent manner. By contrast, early gene upregulation due to risk factors may anticipate features of CV aging in middle-age individuals [51] .
Transcription Factor JunD Regulates Oxidant and Scavenger Enzymes
The Activated Protein-1 (AP) transcription factor JunD is emerging as an important modulator of age-driven mitochondrial oxidative stress [52] . AP-1 is a collection of dimeric complexes made by different members of three families of DNA-binding proteins: Jun, Fos, and ATF/CREB [53] . These members assemble to form AP-1 transcription factors with activities that are strongly influenced by their specific components and their cellular environment. JunD, the most recent gene of the Jun family, regulates cell growth and survival and protects against oxidative stress by modulating genes involved in antioxidant defense and ROS production [54] . Our recent work has shown that in contrast with p66 Shc , JunD is a longevity gene implicated in the preservation of vascular homeostasis during life [25••] . We found that JunD is downregulated by aging both in the mouse aorta and in peripheral monocytes of old as compared with young healthy individuals [25••] .
Young JunD −/− mice showed early endothelial dysfunction and vascular senescence, which were comparable with the one observed in aged WT mice. JunD deletion was indeed associated with upregulation of the aging markers p53 and p16 INK4a , reduced telomerase activity and mitochondrial DNA damage [25••] . Interestingly enough, transient overexpression of JunD was able to rescue endothelial dysfunction in aged mice. Mechanistically, we found that JunD is required for the expression of mitochondrial antioxidant enzymes such as manganese superoxide dismutase and aldehyde dehydrogenase 2 (ALDH-2, see Fig. 1 ). This latter enzyme was almost abolished in young JunD −/− mice compared with age-matched littermates. The relevance of this finding is supported by the notion that ALDH-2 protects against ischemia/ reperfusion injury [55] and cardiac arrhythmias [56] . Moreover, JunD participates to eNOS transcription, thus contributing to preserved NO availability during aging [57] . The transcription factor also modulates the expression and activity of NADPH oxidase in the vasculature [25••] . Indeed, JunD −/− mice display a premature upregulation of NADPH isoform p47phox, Nox2 and Nox4 leading to increased vascular oxidative stress already in early stages of life. Moreover, in our study JunD expression negatively correlated with NADPH subunits in aged individuals. In line with our findings, the lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart [58] . Notably, JunD protein levels are decreased in patients with end-stage heart failure suggesting that the transcription factor may protect against age-related cardiac dysfunction [59] . Based on these recent observations on the role of p66 Shc and JunD in aging, one can postulate that early deregulation of aging and longevity genes may anticipate CV senescence (see Fig. 1 ). The importance of premature senescence in this setting is strengthened by the notion that myocardial infarction and stroke exhibit a strong age dependency [4] .
Mammalian Deacetylase SIRT1
The family of nicotinamide adenine dinucleotide (NAD)-dependent proteins termed sirtuins has recently emerged as an important regulator of CV aging. SIRT1 is considered a major gatekeeper against oxidative stress and tissue inflammation [60] . Increased SIRT1 activity confers resistance to many of the CV sequelae associated with aging [61] . In the heart, SIRT1 overexpression leads to reduced myocardial hypertrophy, interstitial fibrosis, oxidative stress and senescent markers such as p15
INK4b and p19 ARF [62] . Moreover, activation of SIRT1 in endothelial tissues may be of benefit in preserving endothelial cell function during aging [63] . Mice with endothelial specific SIRT1 overexpression on an ApoE −/− genetic background exhibit attenuated development of atherosclerotic lesions [64] . Conversely, SIRT1 insufficiency results in greater foam cell formation and atherosclerosis [65] . In the human endothelium, overexpression of SIRT1 prevents oxidative stress-induced senescence, while its inhibition leads to a premature senescence-like phenotype. Interestingly, immunosuppressant drugs, like sirolimus and everolimus, induce endothelial cellular senescence via SIRT1 downregulation [66] . SIRT1 inhibition also impairs eNOS functionality whereas its activation improves endothelial NO availability [63] . Hence, the SIRT1/NO axis may represent a relevant target against vascular and cardiac senescence.
SIRT1-mediated deacetylation modulates the function of proteins via transcriptional and post-translational changes. A recent study reported that vascular p66
Shc gene transcription may be the result of decreased promoter deacetylation due to downregulation of SIRT1 [67•] . Therefore, one can certainly postulate that SIRT1 and p66
Shc stand along the same molecular pathway involved in the modulation of vascular and myocardial integrity during aging (see Fig. 1 ). Moreover, both SIRT1 and p66
Shc lie upstream and downstream the tumour suppressor p53, critically involved in age-dependent mitochondrial disruption and apoptosis (see Fig. 1 ) [63] . Downregulation of SIRT1 also favours increased acetylation of nuclear factor (NF)-kB p65, leading to its nuclear translocation and transcription of inflammatory genes [63] .
Nuclear Factor-kB p65 NF-κB is an important transcription factor expressed in all mammalian cell types. It is responsible for regulating the gene expression of factors that control cell adhesion, proliferation, inflammation, redox state, and tissue specific enzymes [60] . Activation of NF-kB mediates vascular and myocardial inflammation in metabolic and age-related diseases [68] . A recent study clearly demonstrated that endothelial suppression of NF-kB prolongs lifespan in mice and ameliorates obesityinduced endothelial insulin resistance [69••] . Impaired insulin signalling is indeed an important hallmark linking metabolic disease with premature aging of the CV system [23] . The relevance of these findings is supported by the notion that NF-κB protein is elevated in vascular endothelial cells isolated from obese and aged adults as compared with normal weight and young controls [70] . Moreover, agedependent NFκB activation was associated with systemic inflammation and impaired endothelial dependent dilation [71] . NF-kB is also a potent mediator of age-induced myocardial inflammation and fibrosis. Accordingly, NF-kB suppression, using direct gene delivery of short hairpin p65 RNA, attenuates remodelling and cardiac hypertrophy [72] . These data validate NF-kB as a therapeutic target to prevent cardiac disease in elderly (see Fig. 1 ).
Vascular and Myocardial Repair in Aging: Mechanistic and Therapeutic Insights
Recovery after ischemia or infarction in any organ requires blood vessel growth [73] . The incidence of stroke, claudication and myocardial infarction all increase in elderly patients, and they have worse outcomes when ischemia and infarction does occur. Capillary density as well as angiogenic response are impaired in aged individuals [73] . In this context, senescence of endothelial progenitor cells (EPCs) and early angiogenic outgrowth cells (EOCs) [74] are especially relevant. These cell types significantly contribute to endothelial repair, a phenomenon which is less efficient in aging [75] .
EPCs are thought to directly mediate endothelial regeneration while EOCs represent an heterogeneous pool of cell precursors, mostly of myeloid origin, which favour endothelial healing via a paracrine mechanism [76] . Although we are still far from a clear understanding of these processes, available knowledge support the notion that aging impairs the function of ex-vivo expanded EPCs [77] . Age-related EPC dysfunction is mediated by the imbalance between factors promoting growth, migration/survival and those enhancing oxidative stress/senescence [75] . Hypoxia inducible factor 1α (HIF-1α) induces the expression of stromal cell-derived factor 1 (SDF-1) that enhances the recruitment of EPCs in injured or ischemic tissues in mice. HIF-1α/SDF-1 signalling is impaired in aging and contributes to altered vascular repair (see Fig. 1 ) [78] .
Interestingly, CV risk factors mirror the aging process by impairing EPCs functionality and, hence, the vascular repair process [79, 80] . Indeed, the aging gene p66
Shc is upregulated in EPCs isolated from diabetic subjects and contributes to impaired migration and tube formation [81] . By contrast, vascular repair capacities are preserved in EPCs isolated from p66 Shc−/− diabetic mice [81] . Recent work suggests that microRNAs (miRs) may be involved in the pathogenesis of age-related EPCs dysfunction (see Fig. 1 ) [82, 83] . These small non-coding RNAs orchestrate EPCs functionality by regulating gene expression at the post-transcriptional level [84] . [85••] . Furthermore, miR-34a was found to inhibit EPCmediated angiogenesis by inducing senescence via suppressing SIRT1 [86] .
A recent study from our group showed that reprogramming angiomiR-126 and -130a in angiogenic EOCs and circulating EPCs isolated from patients with heart failure improve cardiac function and vascular repair in mice [87] . These novel data suggest the possibility that in vitro reprogramming of human EPCs may improve vascular repair. Such an observation deserves attention since intracoronary administration of autologous bone marrow-derived mononuclear cells has failed to improve cardiac function in patients with myocardial infarction (MI) [88] .
Cardiac progenitor cells (CPC) are also critically involved in growth and myocyte formation to compensate myocyte loss due to prolonged ischemia [89] . Seminal observations have showed clearly the potential of CPC in preventing adverse cardiac remodelling and failure during myocardial ischemia [90] . Aging causes CPC dysfunction mostly affecting their replicative capacities. In this regard, early loss of Insulin like growth factor-1 (IGF-1) plays a pivotal role (see Fig. 1 ) [91, 92] . A recent study showed that chronological age was a major predictor of five biomarkers of human CPC senescence: telomeric shortening, attenuated telomerase activity, and telomere dysfunction-induced foci as well as p21
Cip1 and p16 INK4a expression [93] .The preliminary findings of the SCIPIO trial suggest that intracoronary infusion of autologous CPC is effective in improving LV systolic function and reducing infarct size in patients with heart failure after myocardial infarction [94] . These encouraging findings provide glimpses for myocardial regeneration in elderly patients with myocardial infarction.
Conclusions
Multiple molecular mechanisms are implicated in early CV aging and disease. Premature activation of aging genes such as p66 Shc and NF-kB as well as downregulation of lifespan determinants JunD and SIRT1 may trigger senescence features, leading to early CV disease. Dysregulation of aging and longevity after a life-time course to CV risk factors support the reprogramming of endothelial and cardiac stem cells as a promising strategy to delay the onset and progression of CV disease.
